{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:50:25Z","timestamp":1792687825206,"version":"4.5.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Venlafaxine, a serotonin-norepinephrine reuptake inhibitor widely prescribed for major depressive disorder and related conditions, remains insufficiently characterized regarding its adverse event profile. This study aimed to comprehensively evaluate the post-marketing safety of venlafaxine using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The data were extracted from the FAERS database from the first quarter (Q1) 2004 to Q2 2025. Adverse drug events were analyzed using the Reporting Odds Ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN), Proportional Reporting Ratio (PRR), and Multi-Item Gamma Poisson Shrinker (MGPS) methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 47,325 venlafaxine-related adverse event reports were analyzed. Disproportionality analysis revealed significant signals for drug ineffectiveness (n = 2,108, ROR = 1.6, PRR = 1.6, \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      = 483.4, IC = 0.7, EBGM = 1.6), drug hypersensitivity (n = 1,014; ROR = 4.9, PRR = 4.8, \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      = 2998.7, IC = 2.2, EBGM = 4.7), and anxiety (n = 198, ROR = 4.3, PRR = 4.2, \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      = 2202.0, IC = 2.0, EBGM = 4.1). Strongest signals (EBGM = 9.9) were observed for suicide attempt, agitated depression, and renal dysplasia. Tachycardia (EBGM = 8.3) was the most frequently reported adverse event among patients under 18\u00a0years, while emotional disorder (EBGM = 9.5) predominated in those aged 65\u00a0years and older. Most adverse events (39.3%) occurred within the first 30\u00a0days of venlafaxine therapy initiation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This pharmacovigilance analysis systematically identified significant safety signals associated with venlafaxine. The findings provide important evidence to support safer clinical use of venlafaxine and may assist in optimizing individualized therapeutic decisions in practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1737113","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:52:19Z","timestamp":1768978339000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["The post-marketing safety of venlafaxine: a real-world two-decade pharmacovigilance study using the FAERS database"],"prefix":"10.3389","volume":"17","author":[{"given":"Santosh","family":"Chokkakula","sequence":"first","affiliation":[{"name":"Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute","place":["Cheongju, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualiang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin Central Hospital of Gynecology Obstetrics","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer A.","family":"Al-Masri","sequence":"additional","affiliation":[{"name":"Department of Physiology, College of Medicine, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiquan","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bommireddy","family":"Naveen","sequence":"additional","affiliation":[{"name":"Department of Chemical and Biological Engineering, Gachon University","place":["Seongnam-Si, Gyeonggi-do, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, College of Basic Medical Sciences, Tianjin Medical University","place":["Tianjin, China"]},{"name":"Department of Public Health, International School, Krirk University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"B1","volume-title":"Diagnostic and statistical manual of mental disorders, text revision","year":"2022"},{"key":"B2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1017\/S1461145705006358","article-title":"Discontinuation symptoms in depression and anxiety disorders","volume":"10","author":"Baldwin","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1080\/15563650.2022.2138762","article-title":"Dose-related hypoglycemia in venlafaxine poisoning: a retrospective cohort study","volume":"60","author":"Bekka","year":"2022","journal-title":"Clin. Toxicol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"704281","DOI":"10.3389\/fcvm.2021.704281","article-title":"Antidepressant drugs effects on blood pressure","volume":"8","author":"Calvi","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fpsyt.2019.00017","article-title":"The efficacy of vortioxetine on anhedonia in patients with major depressive disorder","volume":"10","author":"Cao","year":"2019","journal-title":"Front. Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/bmj.h517","article-title":"Antidepressant use and risk of suicide and attempted suicide or self-harm in people aged 20 to 64: cohort study using a primary care database","author":"Coupland","year":"2015","journal-title":"Bmj"},{"key":"B7","volume-title":"Venlafaxine","year":"2008"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1017\/S0033291717003336","article-title":"Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: results from the WHO World Mental Health (WMH) surveys","volume":"48","author":"Evans-Lacko","year":"2018","journal-title":"Psychol. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.comppsych.2015.12.004","article-title":"Motivational deficits in major depressive disorder: cross-sectional and longitudinal relationships with functional impairment and subjective well-being","volume":"66","author":"Fervaha","year":"2016","journal-title":"ComprPsychiatry"},{"key":"B10","volume-title":"Global burden of disease","year":"2024"},{"key":"B11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/bmb\/ldv034","article-title":"Managing inadequate antidepressant responses in depressive illness","volume":"115","author":"Haddad","year":"2015","journal-title":"Br. Med. Bull."},{"key":"B12","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1001\/archpsyc.63.3.332","article-title":"Suicidality in pediatric patients treated with antidepressant drugs","volume":"63","author":"Hammad","year":"2006","journal-title":"Arch. General Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S2215-0366(19)30221-4","article-title":"Which antidepressant doses are optimal?","volume":"6","author":"Hieronymus","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2165\/00003495-199549020-00010","article-title":"Venlafaxine: a review of its pharmacology and therapeutic potential in depression","volume":"49","author":"Holliday","year":"1995","journal-title":"Drugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1365-2125.2007.02849.x","article-title":"Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases","volume":"64","author":"Howell","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamapsychiatry.2015.0071","article-title":"Large-scale network dysfunction in major depressive disorder: a meta-analysis of resting-state functional connectivity","volume":"72","author":"Kaiser","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1017\/S2045796024000520","article-title":"The risks of adverse events with venlafaxine for adults with major depressive disorder: a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis","volume":"33","author":"Kamp","year":"2024","journal-title":"Epidemiol. Psychiatric Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/s0149-2918(02)80029-7","article-title":"Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study","volume":"24","author":"Kaplan","year":"2002","journal-title":"Clin. Therapeutics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0140-6736(99)11381-3","article-title":"SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression","volume":"355","author":"Kent","year":"2000","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/s0022-3565(24)35098-0","article-title":"Mechanism of sodium channel block by venlafaxine in Guinea pig ventricular myocytes","volume":"291","author":"Khalifa","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"659715","DOI":"10.1155\/2014\/659715","article-title":"Accelerated hypertension after venlafaxine usage","volume":"2014","author":"K\u0131vrak","year":"2014","journal-title":"Case Rep. Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"E568","DOI":"10.1503\/cmaj.78409","article-title":"Venlafaxine-induced hypoglycemia","volume":"193","author":"Kobylianskii","year":"2021","journal-title":"Can. Med. Assoc. J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1017\/S2045796020000633","article-title":"Comorbidity within mental disorders: a comprehensive analysis based on 145 990 survey respondents from 27 countries","volume":"29","author":"McGrath","year":"2020","journal-title":"Epidemiol. Psychiatric Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1017\/S0033291725100652","article-title":"Evidence on antidepressant withdrawal: an appraisal and reanalysis of a recent systematic review","volume":"55","author":"Moncrieff","year":"2025","journal-title":"Psychol. Med."},{"key":"B25","volume-title":"Venlafaxine","year":"2018"},{"key":"B26","doi-asserted-by":"publisher","first-page":"875","DOI":"10.4088\/jcp.v64n0804","article-title":"Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents","volume":"64","author":"Oslin","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4082\/kjfm.20.0100","article-title":"A case report of rare adverse events associated with venlafaxine administration: hypoglycemia and lactic acidosis","volume":"43","author":"\u00d6zdemir","year":"2021","journal-title":"Korean J. Fam. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"09","DOI":"10.33545\/26649241.2025.v7.i1a.20","article-title":"Venlafaxine induced priapism in an adult male: a rare adverse effect","volume":"7","author":"Parinda Parikh","year":"2025","journal-title":"IJPS"},{"key":"B29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1176\/ajp.2007.164.2.290","article-title":"Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials","volume":"164","author":"Rynn","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"B30","article-title":"Anxiety disorders begin in childhood and often evolve into adulthood, re","author":"Rynn","year":"2017","journal-title":"Clin. Man. Child Adolesc. Psychopharmacol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.29011\/2574-7762.000089","article-title":"The tolerability and side effect profile of venlafaxine in a clinical outpatient pediatric population","volume":"7","author":"Simas","year":"2024","journal-title":"J. Psychiatry Cogn. Behav."},{"key":"B32","volume-title":"Venlafaxine. InStatPearls","author":"Singh","year":"2024"},{"key":"B33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1176\/ajp.148.6.705","article-title":"The serotonin syndrome","volume":"148","author":"Sternbach","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1001\/jama.289.23.3135","article-title":"Cost of lost productive work time among US workers with depression","volume":"289","author":"Stewart","year":"2003","journal-title":"JAMA"},{"key":"B35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/bmj.b2880","article-title":"Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration","author":"Stone","year":"2009","journal-title":"Bmj"},{"key":"B36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/clpt.1994.95","article-title":"The effect of renal disease on the disposition of venlafaxine","volume":"56","author":"Troy","year":"1994","journal-title":"Clin. Pharmacol. and Ther."},{"key":"B37","volume-title":"Effexor XR (venlafaxine extended release) prescribing information","year":"2017"},{"key":"B38","unstructured":"Venlafaxine\n          \n          \n          2009"},{"key":"B39","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3109\/15563650.2011.626421","article-title":"Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms","volume":"49","author":"Vinetti","year":"2011","journal-title":"Clin. Toxicol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jad.2017.05.003","article-title":"A systematic review and meta-regression of the prevalence and incidence of perinatal depression","volume":"219","author":"Woody","year":"2017","journal-title":"J. Affect. Disord."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1737113\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:40:51Z","timestamp":1771918851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1737113\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":40,"alternative-id":["10.3389\/fphar.2026.1737113"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1737113","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"article-number":"1737113"}}